0001855763-23-000006.txt : 20231004 0001855763-23-000006.hdr.sgml : 20231004 20231004123449 ACCESSION NUMBER: 0001855763-23-000006 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 EFFECTIVENESS DATE: 20231004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lexaria Bioscience Corp. CENTRAL INDEX KEY: 0001348362 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202000871 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-493776 FILM NUMBER: 231307257 BUSINESS ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 BUSINESS PHONE: 250-765-6424 MAIL ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 FORMER COMPANY: FORMER CONFORMED NAME: LEXARIA CORP. DATE OF NAME CHANGE: 20080229 FORMER COMPANY: FORMER CONFORMED NAME: Lexaria Corp. DATE OF NAME CHANGE: 20051229 D 1 primary_doc.xml X0708 D LIVE 0001348362 Lexaria Bioscience Corp. 100 - 740 MCCURDY ROAD KELOWNA A1 BRITISH COLUMBIA, CANADA V1X 2P7 250-765-6424 NEVADA LEXARIA CORP. Lexaria Corp. Corporation true Christopher Bunka 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Executive Officer Director John Docherty 100 - 740 MCCURDY ROAD KELOWNA A1 BRITISH COLUMBIA, CANADA V1X 2P7 Executive Officer Director NICHOLAS BAXTER 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director TED MCKECHNIE 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1Y 2P7 Director ALBERT REESE 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director CATHERINE TURKEL 100 - 740 McCurdy Road Kelowna A1 BRITISH COLUMBIA, CANADA V1X 2P7 Director Pharmaceuticals $1 - $1,000,000 06b false 2023-10-03 false true false 0 MAXIM GROUP LLC 120708 None None 300 PARK AVENUE, 16TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 1569780 1569780 0 The combined effective offering price of each warrant which was combined with a registered share of common stock or a pre-funded warrant in lieu was $0.97, or aggregate gross proceeds of approximately $1.5 million false 1 109879 0 Maxim Group LLC ("Maxim"), acted as the placement agent in connection with the offering. Maxim received an aggregate fee equal to 5% of the gross proceeds of the offering. 0 false Lexaria Bioscience Corp. /s/ Christopher Bunka Christopher Bunka CEO 2023-10-04